News

The two companies will form a joint development team to oversee the development of tesmilifene in gastric cancer. Shin Poong will fully fund development costs and provide an

The FDA accepted Voyager’s investigational new drug application (IND) and clinical protocol in late December 2004. This unique formulation is being used in the present study in healthy

The multiple sclerosis interferon enhancing therapy (MS-IET) combines interferon-b with Transition’s enhancing agent, EMZ701, with the goal of improving outcomes in multiple sclerosis patients without adding toxicity. The

The Joslin study is a major milestone in understanding why being overweight can lead to a host of health problems, including type 2 diabetes and heart disease. Researchers

In August 2003, a US District Court held Merck’s US patent for once-weekly administration of Fosamax (alendronate sodium) to be valid and infringed by Teva Pharmaceuticals’ abbreviated new

A priority designation can be given to an new drug application (NDA) for Tygacil that, if approved, would be a significant improvement compared with existing treatments. Tygacil is

The fast-track designation will provide for expedited regulatory review for Viprinex (ancrod), which is under development for decreasing disability in patients with acute non-hemorrhagic stroke, treated within six

Under the agreement, BioGeneriX and Neose will enter into an initial three-month research period. Neose will receive a payment and supply of protein for research purposes. During the

The court ruled in CAT’s favor on all counts, denying Abbott’s request for permission to appeal its judgment of 20 December 2004, although Abbott can now apply to